SVCM
DYN icon

Saturn V Capital Management’s Dyne Therapeutics DYN Stock Holding History

Saturn V Capital Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.5M Sell
966,609
-822,007
-46% -$14.2M 3.17% 13
2025
Q4 		$35M Sell
1,788,616
-885,853
-33% -$16.8M 6.42% 6
2025
Q3 		$33.8M Buy
2,674,469
+1,219,040
+84% +$13.9M 7.42% 4
2025
Q2 		$13.9M Buy
+1,455,429
New +$16M 5.62% 9

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Saturn V Capital Management's DYN Position: Q1 2026 in Review

Saturn V Capital Management reduced its Dyne Therapeutics (DYN) stake by 46% in Q1 2026, selling an estimated $14.2M and leaving 966,609 shares worth $17.5M. The position accounts for 3.17% of the portfolio, ranked #13.

Saturn V Capital Management first reported a position in DYN in Q2 2025 and has held it in 4 quarters since. The position peaked at $35M in Q4 2025. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Saturn V Capital Management held 966,609 shares of Dyne Therapeutics worth $17.5M as of Q1 2026.
  • Saturn V Capital Management sold 822,007 Dyne Therapeutics shares in Q1 2026, an estimated $14.2M.
  • Dyne Therapeutics made up 3.17% of Saturn V Capital Management's portfolio in Q1 2026, its #13 holding.
  • Saturn V Capital Management first reported a position in Dyne Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Saturn V Capital Management's Dyne Therapeutics position peaked at $35M in Q4 2025.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Saturn V Capital Management's 13F filing for Q1 2026, filed 15 May 2026.